All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results Hegerova, 2020 0.26 [0.05; 1.49]
Sekine (PLACOVID), 2021 2.14 [0.70; 6.58]
0.83 [0.11 ; 6.52 ] Hegerova, 2020, Sekine (PLACOVID), 2021 2 75% 200 serious not evaluable death D28detailed results AlQahtani, 2020 0.47 [0.04; 5.69]
Aman, 2021 0.51 [0.27; 0.96]
Amra, 2021 0.47 [0.12; 1.93]
Bihariesingh-Sanchit (SuriCovid), 2021 0.39 [0.13; 1.19]
Brunetti, 2020 0.20 [0.05; 0.80]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.02 [0.62; 1.68]
Davoudi-Monfared, 2020 0.30 [0.11; 0.83]
Gharebaghi, 2020 0.00 [0.00; 0.09]
Jamaati, 2021 1.19 [0.38; 3.72]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Karampitsakos, 2021 0.30 [0.11; 0.83]
Li, 2020 0.59 [0.22; 1.59]
MARIPOSA, 2021 1.43 [0.42; 4.87]
NCT04377750 (HMO-0224-20), 0 0.48 [0.15; 1.55]
O’Donnell, 2021 0.47 [0.21; 1.06]
PICP19 (Ray), 2020 0.67 [0.30; 1.51]
PlasmAr, 2020 0.93 [0.47; 1.85]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Raman, 2021 0.49 [0.02; 15.10]
Rashad, 2021 2.86 [1.36; 6.01]
Rashad, 2021 0.35 [0.17; 0.74]
RECOVER, 2021 1.09 [0.38; 3.13]
REMAP-CAP, fixed 7-day course, 2020 1.03 [0.54; 1.98]
REMAP-CAP, shock-dependent course, 2020 1.10 [0.58; 2.10]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shi, 2020 0.53 [0.01; 27.55]
Shu, 2020 0.38 [0.02; 8.14]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.56 [0.34; 7.13]
Veiga, 2021 2.70 [0.92; 7.92]
0.76 [0.60 ; 0.95 ] AlQahtani, 2020, Aman, 2021, Amra, 2021, Bihariesingh-Sanchit (SuriCovid), 2021, Brunetti, 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Davoudi-Monfared, 2020, Gharebaghi, 2020, Jamaati, 2021, Kalil (ACTT-3), 2021, Karampitsakos, 2021, Li, 2020, MARIPOSA, 2021, NCT04377750 (HMO-0224-20), 0, O’Donnell, 2021, PICP19 (Ray), 2020, PlasmAr, 2020, Pouladzadeh, 2021, Raman, 2021, Rashad, 2021, Rashad, 2021, RECOVER, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, Sekine (PLACOVID), 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Tabarsi, 2020, Talaschian, 2021, Veiga, 2021 35 47% 5,651 moderate critical death or transfer to ICUdetailed results Ana-COVID (Huet), 2020 0.22 [0.10; 0.49]
Lopardo, 2021 0.65 [0.35; 1.22]
Tziolos, 2021 0.93 [0.87; 0.99]
0.55 [0.26 ; 1.19 ] Ana-COVID (Huet), 2020, Lopardo, 2021, Tziolos, 2021 3 85% 706 low not evaluable deathsdetailed results AlQahtani, 2020 0.47 [0.04; 5.69]
Aman, 2021 0.51 [0.27; 0.96]
Andrew, 2020 0.76 [0.57; 1.01]
ARI-RAF (Della-Torre), 2020 0.36 [0.08; 1.65]
Bihariesingh-Sanchit (SuriCovid), 2021 0.22 [0.23; 0.21]
Biran, 2020 0.64 [0.47; 0.87]
Brunetti, 2020 0.20 [0.05; 0.80]
Cao, 2020 0.15 [0.01; 3.29]
CAPE-COVID, 2020 0.45 [0.20; 1.02]
CAPSID, 2021 0.84 [0.28; 2.50]
CODEX (Tomazini), 2020 0.97 [0.72; 1.31]
COLCHIVID, 2021 0.69 [0.20; 2.40]
CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25]
Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92]
Davoudi-Monfared, 2020 0.38 [0.16; 0.87]
DEVENT, 0 0.47 [0.22; 1.00]
DEXA-COVID19, 2020 2.00 [0.21; 18.87]
Duan, 2020 0.12 [0.01; 2.86]
Edalatifard, 2020 0.29 [0.15; 0.56]
Gharebaghi, 2020 0.00 [0.00; 0.09]
Guan, 2020 0.67 [0.22; 2.09]
Hamed, 2021 1.83 [0.16; 21.66]
Hegerova, 2020 0.26 [0.05; 1.49]
ILBS-COVID-02 (Bajpai M), 2020 3.82 [0.35; 41.96]
Jamaati, 2021 1.19 [0.38; 3.72]
Jianfeng, 2020 3.02 [1.59; 5.73]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Kumar, 2021 0.06 [0.00; 1.35]
Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12]
Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50]
Li, 2020 0.59 [0.22; 1.59]
Lopardo, 2021 0.57 [0.24; 1.37]
Lu, 2020 3.28 [0.99; 10.90]
Mathilde, 2020 0.25 [0.06; 1.09]
Monreal, 2020 2.46 [1.58; 3.83]
NCT04377750 (HMO-0224-20), 0 0.48 [0.15; 1.55]
O’Donnell, 2021 0.47 [0.21; 1.06]
PICP19 (Ray), 2020 0.67 [0.30; 1.51]
PlasmAr, 2020 0.93 [0.47; 1.85]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Raef, 2020 0.45 [0.22; 0.92]
Rahmani, 2020 0.29 [0.05; 1.56]
Raman, 2021 0.49 [0.02; 15.10]
Rashad, 2021 2.16 [1.14; 4.09]
Rashad, 2021 0.46 [0.24; 0.88]
Rasheed, 2020 0.13 [0.01; 1.09]
RECOVER, 2021 1.09 [0.38; 3.13]
REMAP-CAP (plasma), 2021 0.96 [0.80; 1.15]
REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95]
REMAP-CAP sarilumab, 2021 0.51 [0.25; 1.07]
REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45]
REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53]
Rojas-Marte, 2020 0.62 [0.35; 1.09]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rossotti, 2020 0.50 [0.26; 0.95]
Salton (Methylprednisolone), 2020 0.29 [0.12; 0.72]
sarilumab phase 2 high dose, 0 0.78 [0.34; 1.80]
sarimulab phase 2 low dose, 0 1.51 [0.69; 3.32]
Sean, 2020 0.46 [0.17; 1.25]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shi, 2020 0.53 [0.01; 27.55]
Shu, 2020 0.38 [0.02; 8.14]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
Somers, 2020 0.55 [0.33; 0.91]
Steroids-SARI, 2020 0.91 [0.29; 2.86]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.25 [0.30; 5.14]
TOCI-RAF Study Group (Campochiaro), 2020 0.37 [0.11; 1.23]
Tziolos, 2021 0.47 [0.28; 0.80]
Veiga, 2021 2.70 [0.92; 7.92]
Wang, 2020 1.58 [0.13; 18.81]
Wu, 2020 0.38 [0.20; 0.72]
Zhou, 2020 3.18 [1.63; 6.19]
0.70 [0.55 ; 0.88 ] AlQahtani, 2020, Aman, 2021, Andrew, 2020, ARI-RAF (Della-Torre), 2020, Bihariesingh-Sanchit (SuriCovid), 2021, Biran, 2020, Brunetti, 2020, Cao, 2020, CAPE-COVID, 2020, CAPSID, 2021, CODEX (Tomazini), 2020, COLCHIVID, 2021, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, DEVENT, 0, DEXA-COVID19, 2020, Duan, 2020, Edalatifard, 2020, Gharebaghi, 2020, Guan, 2020, Hamed, 2021, Hegerova, 2020, ILBS-COVID-02 (Bajpai M), 2020, Jamaati, 2021, Jianfeng, 2020, Kalil (ACTT-3), 2021, Kumar, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Li, 2020, Lopardo, 2021, Lu, 2020, Mathilde, 2020, Monreal, 2020, NCT04377750 (HMO-0224-20), 0, O’Donnell, 2021, PICP19 (Ray), 2020, PlasmAr, 2020, Pouladzadeh, 2021, Raef, 2020, Rahmani, 2020, Raman, 2021, Rashad, 2021, Rashad, 2021, Rasheed, 2020, RECOVER, 2021, REMAP-CAP (plasma), 2021, REMAP-CAP (tocilizumab), 2021, REMAP-CAP sarilumab, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rojas-Marte, 2020, Rosas (REMDACTA), 2021, Rossotti, 2020, Salton (Methylprednisolone), 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Sean, 2020, Sekine (PLACOVID), 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Somers, 2020, Steroids-SARI, 2020, Tabarsi, 2020, Talaschian, 2021, TOCI-RAF Study Group (Campochiaro), 2020, Tziolos, 2021, Veiga, 2021, Wang, 2020, Wu, 2020, Zhou, 2020 79 92% 13,607 moderate critical deaths (time to event analysis only)detailed results Andrew, 2020 0.76 [0.57; 1.01]
ARI-RAF (Della-Torre), 2020 0.36 [0.08; 1.65]
Bihariesingh-Sanchit (SuriCovid), 2021 0.22 [0.23; 0.21]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
Davoudi-Monfared, 2020 0.38 [0.16; 0.87]
Edalatifard, 2020 0.29 [0.15; 0.56]
Jianfeng, 2020 3.02 [1.59; 5.73]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
PlasmAr, 2020 0.93 [0.47; 1.85]
Rashad, 2021 2.16 [1.14; 4.09]
Rashad, 2021 0.46 [0.24; 0.88]
REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45]
REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Salton (Methylprednisolone), 2020 0.29 [0.12; 0.72]
Somers, 2020 0.55 [0.33; 0.91]
Talaschian, 2021 1.25 [0.30; 5.14]
0.78 [0.48 ; 1.28 ] Andrew, 2020, ARI-RAF (Della-Torre), 2020, Bihariesingh-Sanchit (SuriCovid), 2021, COVACTA (Rosas), 2020, CP-COVID-19, 2021, Davoudi-Monfared, 2020, Edalatifard, 2020, Jianfeng, 2020, Kalil (ACTT-3), 2021, PlasmAr, 2020, Rashad, 2021, Rashad, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, Salton (Methylprednisolone), 2020, Somers, 2020, Talaschian, 2021 18 96% 3,946 moderate critical clinical deteriorationdetailed results Ana-COVID (Huet), 2020 0.22 [0.10; 0.49]
Cao, 2020 0.11 [0.01; 2.21]
CAPSID, 2021 0.63 [0.29; 1.40]
CODEX (Tomazini), 2020 0.66 [0.43; 1.02]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20]
Salton (Methylprednisolone), 2020 0.41 [0.24; 0.71]
Shu, 2020 0.27 [0.01; 5.58]
0.48 [0.34 ; 0.66 ] Ana-COVID (Huet), 2020, Cao, 2020, CAPSID, 2021, CODEX (Tomazini), 2020, CORIMUNO-TOCI-1 (Group 1), 2020, Salton (Methylprednisolone), 2020, Shu, 2020 7 22% 885 serious not evaluable clinical improvementdetailed results Cao, 2020 1.67 [0.84; 3.33]
CAPSID, 2021 1.58 [0.71; 3.49]
COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Davoudi-Monfared, 2020 1.10 [0.64; 1.88]
Edalatifard, 2020 12.00 [2.39; 60.20]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Li, 2020 1.40 [0.79; 2.49]
Lopardo, 2021 1.61 [0.75; 3.49]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 0.81 [0.50; 1.31]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15]
REMAP-CAP sarilumab, 2021 1.76 [1.12; 2.78]
REMAP-CAP, fixed 7-day course, 2020 1.43 [0.91; 2.26]
REMAP-CAP, shock-dependent course, 2020 1.22 [0.76; 1.95]
sarilumab phase 2 high dose, 0 2.09 [1.00; 4.36]
sarimulab phase 2 low dose, 0 1.51 [0.73; 3.11]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shu, 2020 10.27 [1.17; 90.18]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
1.37 [1.17 ; 1.60 ] Cao, 2020, CAPSID, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Davoudi-Monfared, 2020, Edalatifard, 2020, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Li, 2020, Lopardo, 2021, O’Donnell, 2021, PlasmAr, 2020, Pouladzadeh, 2021, REMAP-CAP (tocilizumab), 2021, REMAP-CAP sarilumab, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Sekine (PLACOVID), 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 24 56% 5,284 moderate critical clinical improvement (14-day)detailed results Cao, 2020 2.00 [0.58; 6.94]
COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09]
Kalil (ACTT-3), 2021 1.01 [0.79; 1.29]
Li, 2020 2.27 [0.90; 5.72]
REMAP-CAP sarilumab, 2021 1.86 [1.20; 2.87]
REMAP-CAP, fixed 7-day course, 2020 1.29 [0.82; 2.03]
REMAP-CAP, shock-dependent course, 2020 1.03 [0.65; 1.64]
Shu, 2020 10.27 [1.17; 90.18]
1.43 [1.08 ; 1.91 ] Cao, 2020, COV-BARRIER (critically ill), 2022, Kalil (ACTT-3), 2021, Li, 2020, REMAP-CAP sarilumab, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Shu, 2020 8 51% 2,203 moderate serious clinical improvement (21-day)detailed results Cao, 2020 1.50 [0.22; 10.08]
1.50 [0.22 ; 10.08 ] Cao, 2020 1 0% 41 NA not evaluable clinical improvement (28-day)detailed results Brunetti, 2020 3.50 [1.19; 10.29]
COV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Li, 2020 1.42 [0.65; 3.10]
O’Donnell, 2021 1.38 [0.73; 2.61]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shu, 2020 3.68 [0.18; 75.54]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
1.48 [1.06 ; 2.05 ] Brunetti, 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Li, 2020, O’Donnell, 2021, Pouladzadeh, 2021, Sekine (PLACOVID), 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 10 44% 1,217 moderate critical clinical improvement (7-day)detailed results Cao, 2020 2.38 [0.38; 14.70]
Li, 2020 0.98 [0.27; 3.58]
Shu, 2020 6.72 [1.50; 30.07]
2.39 [0.73 ; 7.80 ] Cao, 2020, Li, 2020, Shu, 2020 3 45% 185 moderate not evaluable clinical improvement (time to event analysis only)detailed results Cao, 2020 1.67 [0.84; 3.33]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18]
Davoudi-Monfared, 2020 1.10 [0.64; 1.88]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54]
Li, 2020 1.40 [0.79; 2.49]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 1.00 [0.76; 1.32]
Rahmani, 2020 3.41 [1.33; 8.73]
1.15 [1.00 ; 1.33 ] Cao, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Li, 2020, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 2020 11 34% 2,404 moderate critical death or ventilationdetailed results CAPE-COVID, 2020 0.71 [0.37; 1.35]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31]
REMAP-CAP, fixed 7-day course, 2020 2.74 [1.16; 6.46]
REMAP-CAP, shock-dependent course, 2020 1.24 [0.55; 2.78]
Rosas (REMDACTA), 2021 0.98 [0.72; 1.34]
sarilumab phase 2 high dose, 0 0.39 [0.18; 0.82]
sarimulab phase 2 low dose, 0 0.70 [0.34; 1.44]
Veiga, 2021 1.54 [0.65; 3.63]
0.91 [0.63 ; 1.30 ] CAPE-COVID, 2020, CORIMUNO-TOCI-1 (Group 1), 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Veiga, 2021 8 56% 1,544 moderate not evaluable hospital dischargedetailed results Brunetti, 2020 5.00 [1.25; 20.04]
CAPE-COVID, 2020 1.67 [0.87; 3.19]
COLCHIVID, 2021 1.13 [0.76; 1.67]
Davoudi-Monfared, 2020 1.96 [0.76; 5.03]
MARIPOSA, 2021 0.88 [0.55; 1.40]
Rahmani, 2020 3.44 [0.64; 18.49]
Rosas (REMDACTA), 2021 0.97 [0.79; 1.20]
1.24 [0.92 ; 1.67 ] Brunetti, 2020, CAPE-COVID, 2020, COLCHIVID, 2021, Davoudi-Monfared, 2020, MARIPOSA, 2021, Rahmani, 2020, Rosas (REMDACTA), 2021 7 48% 1,137 low serious mechanical ventilationdetailed results AlQahtani, 2020 0.67 [0.22; 2.02]
CAPE-COVID, 2020 0.95 [0.44; 2.04]
COVACTA (Rosas), 2020 0.67 [0.39; 1.14]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67]
Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67]
Davoudi-Monfared, 2020 0.72 [0.29; 1.76]
Hamed, 2021 3.15 [0.57; 17.48]
Jamaati, 2021 1.38 [0.45; 4.20]
MARIPOSA, 2021 0.88 [0.37; 2.10]
O’Donnell, 2021 1.50 [0.47; 4.82]
PlasmAr, 2020 0.86 [0.39; 1.93]
Rahmani, 2020 0.29 [0.05; 1.56]
Salton (Methylprednisolone), 2020 0.50 [0.24; 1.04]
sarilumab phase 2 high dose, 0 0.27 [0.10; 0.71]
sarimulab phase 2 low dose, 0 0.28 [0.11; 0.73]
Shu, 2020 0.59 [0.02; 14.04]
Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48]
Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07]
Tabarsi, 2020 1.49 [0.59; 3.78]
0.73 [0.55 ; 0.95 ] AlQahtani, 2020, CAPE-COVID, 2020, COVACTA (Rosas), 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, Hamed, 2021, Jamaati, 2021, MARIPOSA, 2021, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 2020, Salton (Methylprednisolone), 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Tabarsi, 2020 19 20% 2,034 moderate low mechanical ventilation (time to event analysis only)detailed results CP-COVID-19, 2021 0.66 [0.25; 1.72]
0.66 [0.25 ; 1.72 ] CP-COVID-19, 2021 1 0% 100 NA not evaluable radiologic improvement (14-day)detailed results Cao, 2020 5.54 [1.01; 30.50]
Jamaati, 2021 4.89 [1.15; 20.79]
Tabarsi, 2020 2.33 [0.45; 12.00]
4.02 [1.61 ; 10.05 ] Cao, 2020, Jamaati, 2021, Tabarsi, 2020 3 0% 175 moderate not evaluable viral clearance detailed results CP-COVID-19, 2021 1.12 [0.16; 7.84]
Raman, 2021 36.42 [10.85; 122.18]
6.97 [0.23 ; 210.35 ] CP-COVID-19, 2021, Raman, 2021 2 89% 200 moderate not evaluable viral clearance by day 14detailed results CP-COVID-19, 2021 1.51 [0.33; 6.94]
Raman, 2021 36.42 [10.85; 122.18]
7.68 [0.34 ; 173.70 ] CP-COVID-19, 2021, Raman, 2021 2 90% 200 moderate not evaluable ICU admissiondetailed results COVACTA (Rosas), 2020 0.48 [0.25; 0.94]
CP-COVID-19, 2021 0.82 [0.35; 1.91]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71]
Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94]
Hamed, 2021 3.15 [0.57; 17.48]
Lopardo, 2021 0.67 [0.35; 1.28]
Rahmani, 2020 0.37 [0.14; 1.00]
Salton (Methylprednisolone), 2020 0.51 [0.25; 1.06]
Tabarsi, 2020 0.56 [0.18; 1.74]
Tziolos, 2021 0.19 [0.10; 0.39]
0.53 [0.36 ; 0.76 ] COVACTA (Rosas), 2020, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Hamed, 2021, Lopardo, 2021, Rahmani, 2020, Salton (Methylprednisolone), 2020, Tabarsi, 2020, Tziolos, 2021 10 39% 1,353 moderate low off oxygenationdetailed results Davoudi-Monfared, 2020 8.57 [1.43; 51.36]
ILBS-COVID-02 (Bajpai M), 2020 0.26 [0.02; 2.88]
sarilumab phase 2 high dose, 0 1.99 [0.95; 4.15]
sarimulab phase 2 low dose, 0 1.07 [0.52; 2.21]
1.62 [0.67 ; 3.92 ] Davoudi-Monfared, 2020, ILBS-COVID-02 (Bajpai M), 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0 4 58% 331 serious not evaluable recoverydetailed results COV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20]
Talaschian, 2021 0.64 [0.14; 2.92]
1.30 [0.64 ; 2.66 ] COV-BARRIER (critically ill), 2022, Talaschian, 2021 2 9% 137 low not evaluable related AE (TRAE)detailed results Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93]
1.26 [0.14 ; 11.07 ] Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 2 0% 25 moderate not evaluable serious adverse eventsdetailed results Cao, 2020 0.11 [0.01; 2.21]
CODEX (Tomazini), 2020 0.53 [0.17; 1.62]
COVACTA (Rosas), 2020 0.81 [0.54; 1.22]
Edalatifard, 2020 0.81 [0.11; 6.17]
Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12]
Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51]
O’Donnell, 2021 0.64 [0.35; 1.17]
PlasmAr, 2020 1.40 [0.78; 2.51]
Raman, 2021 0.49 [0.02; 15.10]
REMAP-CAP (plasma), 2021 2.28 [1.17; 4.46]
REMAP-CAP, fixed 7-day course, 2020 3.01 [0.33; 27.32]
REMAP-CAP, shock-dependent course, 2020 3.68 [0.42; 31.96]
Rosas (REMDACTA), 2021 0.83 [0.59; 1.18]
Sekine (PLACOVID), 2021 1.14 [0.88; 1.48]
Shi, 2020 1.08 [0.04; 32.96]
Talaschian, 2021 7.93 [0.37; 171.38]
Veiga, 2021 1.66 [0.60; 4.59]
1.07 [0.87 ; 1.32 ] Cao, 2020, CODEX (Tomazini), 2020, COVACTA (Rosas), 2020, Edalatifard, 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, O’Donnell, 2021, PlasmAr, 2020, Raman, 2021, REMAP-CAP (plasma), 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, Sekine (PLACOVID), 2021, Shi, 2020, Talaschian, 2021, Veiga, 2021 17 26% 5,521 moderate low superinfectiondetailed results CAPE-COVID, 2020 0.81 [0.49; 1.34]
Davoudi-Monfared, 2020 2.41 [0.75; 7.73]
Rahmani, 2020 0.18 [0.02; 1.59]
Somers, 2020 3.27 [1.66; 6.43]
1.32 [0.48 ; 3.60 ] CAPE-COVID, 2020, Davoudi-Monfared, 2020, Rahmani, 2020, Somers, 2020 4 80% 450 serious not evaluable acute kidney injury detailed results Tziolos, 2021 0.43 [0.14; 1.34]
0.43 [0.14 ; 1.34 ] Tziolos, 2021 1 0% 369 NA not evaluable adverse eventsdetailed results Cao, 2020 1.60 [0.38; 6.81]
COVACTA (Rosas), 2020 0.87 [0.52; 1.45]
Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69]
Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27]
Raman, 2021 1.36 [0.56; 3.30]
Rosas (REMDACTA), 2021 1.32 [0.92; 1.89]
Sekine (PLACOVID), 2021 1.08 [0.85; 1.38]
Shi, 2020 0.88 [0.38; 2.03]
Shu, 2020 2.48 [0.05; 132.54]
Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71]
Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01]
Veiga, 2021 1.65 [0.81; 3.37]
1.13 [0.96 ; 1.32 ] Cao, 2020, COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Raman, 2021, Rosas (REMDACTA), 2021, Sekine (PLACOVID), 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Veiga, 2021 12 0% 2,178 moderate low arrhythmiadetailed results Tziolos, 2021 0.16 [0.03; 0.90]
0.16 [0.03 ; 0.90 ] Tziolos, 2021 1 0% 369 NA not evaluable elevated liver enzymesdetailed results Tziolos, 2021 0.52 [0.18; 1.51]
0.52 [0.18 ; 1.51 ] Tziolos, 2021 1 0% 369 NA not evaluable Myocardial infarction detailed results Tziolos, 2021 0.87 [0.19; 3.92]
0.87 [0.19 ; 3.92 ] Tziolos, 2021 1 0% 369 NA not evaluable venous thromboembolism detailed results Tziolos, 2021 5.23 [0.42; 65.62]
5.23 [0.42 ; 65.62 ] Tziolos, 2021 1 0% 369 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-27 14:29 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 91
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290